The most common subtype is Luminal A accounting for about 70% of breast cancers, followed by triple-negative (15–20%) and Luminal B (10–20%), with the HER2-enriched subtype being the rarest, at 5–15% of all cases [5]. Here, ERBB2 is linked to breast cancer.